Chord Therapeutics SA

Merck KGaA 's chief medical officer Danny Bar-Zohar has lifted the lid on the firm's plans to double R&D productivity with the target of introducing one new product every 18 months on average, but it

When Merck KGaA presented its financials for 2021 last month, it was striking to see that a number of drugs that got their first approvals last century were still making very healthy contributions t

When Merck KGaA presented its financials for 2021 earlier this month, it was striking to see that a number of drugs that got their first approvals last century were still making very healthy contrib

Merck KGaA is taking a relaxed view to M&A and licensing activities in its healthcare segment, believing its existing portfolio and pipeline is enough to be focusing on for the time being. So said CE